Ignite Creation Date:
2024-05-06 @ 6:22 PM
Last Modification Date:
2024-10-26 @ 2:47 PM
Study NCT ID:
NCT05646381
Status:
RECRUITING
Last Update Posted:
2024-06-24
First Post:
2022-12-02
Brief Title:
A Multicenter Trial Assessing the Impact of Lipoproteina Lowering With Pelacarsen TQJ230 on the Progression of Calcific Aortic Valve Stenosis
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
A Randomized Double-blind Placebo-controlled Multicenter Trial Assessing the Impact of Lipoproteina Lowering With Pelacarsen TQJ230 on the Progression of Calcific Aortic Valve Stenosis LpaFRONTIERS CAVS
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the efficacy safety and tolerability of pelacarsen TQJ230 administered subcutaneously once monthly compared to placebo in slowing the progression of calcific aortic valve stenosis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None